Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: A systematic literature review

This systematic review assessed outcomes of inotuzumab ozogamicin in relapsed/refractory ALL. CD22-positive patients in first salvage with normal liver function, no prior liver disease, and HSCT eligibility showed improved outcomes. Reduced veno-occlusive disease risk was linked to avoiding dual alkylators. Limitations included potential publication bias and language restrictions.